Srikripa Devarakonda
Stock Analyst at Truist Securities
(4.31)
# 408
Out of 5,132 analysts
84
Total ratings
56.58%
Success rate
16.71%
Average return
Main Sectors:
Stocks Rated by Srikripa Devarakonda
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BIIB Biogen | Maintains: Hold | $190 → $193 | $196.52 | -1.79% | 6 | Feb 9, 2026 | |
| CYTK Cytokinetics | Maintains: Buy | $84 → $92 | $66.26 | +38.85% | 5 | Feb 3, 2026 | |
| PTGX Protagonist Therapeutics | Maintains: Buy | $88 → $110 | $81.49 | +34.99% | 4 | Jan 5, 2026 | |
| SEPN Septerna | Initiates: Buy | $34 | $27.50 | +23.64% | 1 | Dec 15, 2025 | |
| KYMR Kymera Therapeutics | Maintains: Buy | $80 → $116 | $82.34 | +40.88% | 6 | Dec 9, 2025 | |
| TERN Terns Pharmaceuticals | Maintains: Buy | $35 → $56 | $37.79 | +48.19% | 4 | Dec 9, 2025 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Buy | $580 → $640 | $464.71 | +37.72% | 2 | Nov 19, 2025 | |
| INCY Incyte | Reiterates: Hold | $79 → $93 | $101.10 | -8.01% | 12 | Oct 29, 2025 | |
| SRRK Scholar Rock Holding | Maintains: Buy | $54 → $44 | $45.98 | -4.31% | 5 | Oct 20, 2025 | |
| VTRS Viatris | Initiates: Buy | $15 | $15.77 | -4.88% | 1 | Oct 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $50 | $38.01 | +31.54% | 1 | Oct 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $940 → $812 | $803.17 | +1.10% | 8 | Aug 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $21 → $11 | $11.65 | -5.58% | 1 | May 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $43 → $25 | $16.56 | +50.97% | 5 | Apr 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $1,029 → $1,038 | $1,040.00 | -0.19% | 4 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $211 → $217 | $231.50 | -6.26% | 3 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $36 → $32 | $27.58 | +16.03% | 1 | Dec 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $33 → $50 | $30.01 | +66.61% | 6 | Nov 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $54 | $1.25 | +4,220.00% | 1 | Sep 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $18 → $15 | $5.82 | +157.73% | 7 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $36 | $15.60 | +130.77% | 1 | Jul 31, 2024 |
Biogen
Feb 9, 2026
Maintains: Hold
Price Target: $190 → $193
Current: $196.52
Upside: -1.79%
Cytokinetics
Feb 3, 2026
Maintains: Buy
Price Target: $84 → $92
Current: $66.26
Upside: +38.85%
Protagonist Therapeutics
Jan 5, 2026
Maintains: Buy
Price Target: $88 → $110
Current: $81.49
Upside: +34.99%
Septerna
Dec 15, 2025
Initiates: Buy
Price Target: $34
Current: $27.50
Upside: +23.64%
Kymera Therapeutics
Dec 9, 2025
Maintains: Buy
Price Target: $80 → $116
Current: $82.34
Upside: +40.88%
Terns Pharmaceuticals
Dec 9, 2025
Maintains: Buy
Price Target: $35 → $56
Current: $37.79
Upside: +48.19%
Madrigal Pharmaceuticals
Nov 19, 2025
Maintains: Buy
Price Target: $580 → $640
Current: $464.71
Upside: +37.72%
Incyte
Oct 29, 2025
Reiterates: Hold
Price Target: $79 → $93
Current: $101.10
Upside: -8.01%
Scholar Rock Holding
Oct 20, 2025
Maintains: Buy
Price Target: $54 → $44
Current: $45.98
Upside: -4.31%
Viatris
Oct 15, 2025
Initiates: Buy
Price Target: $15
Current: $15.77
Upside: -4.88%
Oct 15, 2025
Initiates: Buy
Price Target: $50
Current: $38.01
Upside: +31.54%
Aug 11, 2025
Maintains: Buy
Price Target: $940 → $812
Current: $803.17
Upside: +1.10%
May 5, 2025
Downgrades: Hold
Price Target: $21 → $11
Current: $11.65
Upside: -5.58%
Apr 9, 2025
Maintains: Buy
Price Target: $43 → $25
Current: $16.56
Upside: +50.97%
Feb 3, 2025
Maintains: Buy
Price Target: $1,029 → $1,038
Current: $1,040.00
Upside: -0.19%
Feb 3, 2025
Maintains: Buy
Price Target: $211 → $217
Current: $231.50
Upside: -6.26%
Dec 18, 2024
Maintains: Buy
Price Target: $36 → $32
Current: $27.58
Upside: +16.03%
Nov 27, 2024
Maintains: Buy
Price Target: $33 → $50
Current: $30.01
Upside: +66.61%
Sep 27, 2024
Upgrades: Buy
Price Target: $54
Current: $1.25
Upside: +4,220.00%
Aug 13, 2024
Maintains: Buy
Price Target: $18 → $15
Current: $5.82
Upside: +157.73%
Jul 31, 2024
Initiates: Buy
Price Target: $36
Current: $15.60
Upside: +130.77%